Trial Profile

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Surovatamig (Primary) ; Surovatamig (Primary) ; Betamethasone sodium phosphate; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vinorelbine; Vinorelbine
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions
Acronyms Soundtrack-E
Sponsors AstraZeneca; AstraZeneca AB

15 Apr 2026 Planned number of patients changed from 276 to 408.
13 Apr 2026 Protocol has been amended to include one new arm (Experimental: Substudy 3 (LBCL): Cohort 3B 3SUD (Surovatamig + RCHOP)), it has changed from 6 to 7.
13 Apr 2026 Planned End Date changed from 28 Feb 2028 to 11 Jun 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com